CY1116435T1 - Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων - Google Patents
Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτωνInfo
- Publication number
- CY1116435T1 CY1116435T1 CY20151100519T CY151100519T CY1116435T1 CY 1116435 T1 CY1116435 T1 CY 1116435T1 CY 20151100519 T CY20151100519 T CY 20151100519T CY 151100519 T CY151100519 T CY 151100519T CY 1116435 T1 CY1116435 T1 CY 1116435T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- pharmaceutical compositions
- este
- boronic
- compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει νέες ενώσεις χρήσιμες ως αναστολείς πρωτεασώματος. Η εφεύρεση επίσης παρέχει φαρμακευτικές συνθέσεις που περιλαμβάνουν τις ενώσεις της εφεύρεσης και μεθόδους χρήσης των συνθέσεων στη θεραπεία διαφόρων ασθενειών.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13224408P | 2008-06-17 | 2008-06-17 | |
US21149909P | 2009-03-31 | 2009-03-31 | |
EP09767050.9A EP2318419B1 (en) | 2008-06-17 | 2009-06-16 | Boronate ester compounds and pharmaceutical compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116435T1 true CY1116435T1 (el) | 2017-02-08 |
Family
ID=41061278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100519T CY1116435T1 (el) | 2008-06-17 | 2015-06-16 | Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων |
Country Status (38)
Country | Link |
---|---|
US (17) | US20090325903A1 (el) |
EP (6) | EP2730579A1 (el) |
JP (9) | JP5566380B2 (el) |
KR (5) | KR101690571B1 (el) |
CN (10) | CN107266480A (el) |
AR (1) | AR072162A1 (el) |
AU (1) | AU2009260778B2 (el) |
BR (4) | BRPI0915300C1 (el) |
CA (2) | CA2921946C (el) |
CL (1) | CL2010001475A1 (el) |
CO (1) | CO6321289A2 (el) |
CR (3) | CR11850A (el) |
CY (1) | CY1116435T1 (el) |
DK (2) | DK2730581T3 (el) |
DO (1) | DOP2010000384A (el) |
EA (4) | EA201500431A1 (el) |
EC (2) | ECSP11010763A (el) |
ES (2) | ES2585114T3 (el) |
GE (2) | GEP201706703B (el) |
HK (9) | HK1198252A1 (el) |
HR (1) | HRP20150592T1 (el) |
IL (3) | IL210056B (el) |
MA (1) | MA32471B1 (el) |
MX (4) | MX349769B (el) |
MY (2) | MY171021A (el) |
NO (1) | NO2017016I1 (el) |
NZ (4) | NZ624122A (el) |
PE (5) | PE20141078A1 (el) |
PH (3) | PH12015501193A1 (el) |
PL (1) | PL2318419T3 (el) |
PT (2) | PT2318419E (el) |
RS (1) | RS54020B1 (el) |
SG (2) | SG194349A1 (el) |
SI (1) | SI2318419T1 (el) |
TW (3) | TWI542351B (el) |
UA (1) | UA115131C2 (el) |
WO (1) | WO2009154737A1 (el) |
ZA (4) | ZA201009177B (el) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2623113T3 (pl) | 2005-11-09 | 2018-05-30 | Onyx Therapeutics, Inc. | Związek do hamowania enzymu |
SI2041158T1 (sl) | 2006-06-19 | 2013-09-30 | Onyx Therapeutics, Inc. | Peptidni epoksiketoni za inhibicijo proteasomov |
ES2684340T3 (es) | 2007-10-04 | 2018-10-02 | Onyx Therapeutics, Inc. | Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos |
ES2585114T3 (es) * | 2008-06-17 | 2016-10-03 | Millennium Pharmaceuticals, Inc. | Compuestos de ésteres boronato y composiciones farmacéuticas de los mismos |
KR101023994B1 (ko) | 2008-08-28 | 2011-03-28 | 한국생산기술연구원 | 디지털 밴드용 커넥터, 리셉터클 및 커넥터 조립체 |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
US20110236428A1 (en) | 2008-10-21 | 2011-09-29 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
AU2011223795B2 (en) | 2010-03-01 | 2015-11-05 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
US8962572B2 (en) | 2010-10-05 | 2015-02-24 | Fresenius Kabi Usa, Llc | Bortezomib formulations |
CN102784114B (zh) * | 2011-05-14 | 2016-03-02 | 山东新时代药业有限公司 | 一种硼替佐米冻干粉针及其制备方法 |
CA2833775A1 (en) | 2011-06-22 | 2012-12-27 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP6397765B2 (ja) | 2011-11-11 | 2018-09-26 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | プロテアソーム阻害剤に応答するバイオマーカー |
WO2013071163A2 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharamaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
US9732101B2 (en) | 2012-01-18 | 2017-08-15 | Wisconsin Alumni Research Foundation | Bioreversible boronates for delivery of molecules into cells |
US9234048B2 (en) | 2012-01-18 | 2016-01-12 | Wisconsin Alumni Research Foundation | Boronate-mediated delivery of molecules into cells |
CA2862320A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Method of treatment of nasopharyngeal cancer |
WO2013112601A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
WO2013128419A2 (en) * | 2012-03-02 | 2013-09-06 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising boronic acid compounds |
CA2784240C (en) | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Stable bortezomib formulations |
EP2869820A4 (en) | 2012-07-09 | 2016-02-17 | Onyx Therapeutics Inc | PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS |
ITMI20121394A1 (it) * | 2012-08-06 | 2014-02-07 | Chemi Spa | Esteri di bortezomib e loro formulazioni |
US20170035917A1 (en) * | 2013-06-10 | 2017-02-09 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
JP6165986B2 (ja) * | 2013-08-23 | 2017-07-19 | シントン・ビー.ブイ.Synthon B.V. | ボルテゾミブを含む医薬組成物 |
BR112016007237A2 (pt) * | 2013-10-03 | 2017-09-12 | Millennium Pharm Inc | método para a profilaxia ou tratamento do lúpus eritematoso sistêmico e/ou nefrite lúpica |
US10167311B2 (en) | 2014-02-03 | 2019-01-01 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
WO2015151775A1 (ja) * | 2014-03-31 | 2015-10-08 | 富士フイルム株式会社 | 水分解用光電極、水分解装置 |
UY36132A (es) | 2014-05-20 | 2015-11-30 | Millennium Pharm Inc | Métodos para terapia de cáncer |
EP3177292B1 (en) | 2014-08-07 | 2020-11-25 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
EP3212196A4 (en) | 2014-10-29 | 2018-07-11 | Wisconsin Alumni Research Foundation | Boronic acid inhibitors of hiv protease |
EP3031811A1 (en) | 2014-12-09 | 2016-06-15 | Teva Pharmaceuticals Ltd. | Malic acid esters of bortezomib |
MA41505A (fr) | 2015-02-11 | 2017-12-19 | Millennium Pharm Inc | Nouvelle forme cristalline d'un inhibiteur de protéasome |
MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
CZ2015233A3 (cs) | 2015-04-03 | 2016-10-12 | Zentiva, K.S. | Způsob přípravy Ixazomib citrátu |
CZ2015253A3 (cs) | 2015-04-15 | 2016-10-26 | Zentiva, K.S. | Nové formy Ixazomib citrátu |
EP3310360B1 (en) * | 2015-06-19 | 2024-03-27 | Beijing Artivila BioPharma Co. Ltd. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
US10144761B2 (en) * | 2015-06-19 | 2018-12-04 | Hanlin Scientific Inc. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
EP3120836A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Gebrauchsfertige bortezomib-lösung |
EP3120837A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Verfahren zur herstellung einer bortezomibester-lösung |
US20180282351A1 (en) * | 2015-09-16 | 2018-10-04 | Mylan Laboratories Ltd | Amorphous Ixazomib Citrate |
CN106608883A (zh) * | 2015-10-21 | 2017-05-03 | 北京大学 | 蛋白酶体抑制剂mln9708的合成方法 |
US11268154B2 (en) | 2015-11-04 | 2022-03-08 | Takeda Pharmaceutical Company Limited | Methods for the identification, evaluation and treatment of patients having multiple myeloma |
CN106986884A (zh) * | 2016-01-20 | 2017-07-28 | 成都贝斯凯瑞生物科技有限公司 | 一种高效的高纯度含硼化合物制备方法 |
CN105622658B (zh) * | 2016-03-18 | 2018-06-19 | 中国药科大学 | 非肽类蛋白酶体抑制剂、其药物组合物、制备方法和应用 |
WO2017163190A1 (en) * | 2016-03-23 | 2017-09-28 | Dr. Reddy’S Laboratories Limited | Amorphous ixazomib citrate and solid dispersion thereof |
CN107224569A (zh) * | 2016-03-26 | 2017-10-03 | 复旦大学 | 一种硼替佐米水溶性药用组合物及其制备方法和用途 |
CZ2016204A3 (cs) | 2016-04-08 | 2017-11-01 | Zentiva, K.S. | Formulace Ixazomib citrátu formy 3 |
US10604537B2 (en) | 2016-06-21 | 2020-03-31 | Teva Pharmaceuticals International Gmbh | Solid state forms of ixazomib citrate |
US10995103B2 (en) | 2016-07-25 | 2021-05-04 | Shenzhen Targetrx, Inc. | Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof |
JP2019524780A (ja) * | 2016-08-04 | 2019-09-05 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | プロテアソーム阻害剤及び抗cd30抗体の組み合わせ |
WO2018133661A1 (zh) * | 2017-01-23 | 2018-07-26 | 成都奥璟生物科技有限公司 | 一种新的硼酸衍生物及其药物组合物 |
EP3589659A4 (en) | 2017-02-28 | 2021-03-24 | Mayo Foundation for Medical Education and Research | CANCER TREATMENT COMPOUNDS AND METHODS |
WO2018158697A1 (en) | 2017-03-03 | 2018-09-07 | Fresenius Kabi Oncology Limited | A process for the preparation of ixazomib citrate |
WO2018173071A1 (en) * | 2017-03-20 | 2018-09-27 | Msn Laboratories Private Limited, R&D Center | Novel crystalline forms of ixazomib citrate and its process for preparation thereof |
CN106916177B (zh) * | 2017-03-23 | 2019-04-23 | 南京陵瑞医药科技有限公司 | 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途 |
CN108794516A (zh) * | 2017-04-26 | 2018-11-13 | 上海时莱生物技术有限公司 | 硼酸和硼酸酯类化合物及其制备方法和用途 |
CN108794520B (zh) * | 2017-05-02 | 2020-07-24 | 北京大学 | 包括埃沙佐米在内的硼酸柠檬酸酯类化合物的合成方法 |
CN109305980B (zh) * | 2017-07-28 | 2022-10-11 | 成都奥璟生物科技有限公司 | 一种硼酸酯化合物、其合成方法及其用途 |
JP7189203B2 (ja) | 2017-08-24 | 2022-12-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ボロン酸誘導体 |
EP3672978B1 (en) | 2017-08-25 | 2021-10-06 | Synthon B.V. | Process for making ixazomib and its intermediates |
CN111065641A (zh) * | 2017-09-02 | 2020-04-24 | 太阳制药工业有限公司 | 柠檬酸伊沙佐米的制备方法 |
US11401334B2 (en) | 2017-09-14 | 2022-08-02 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitor |
WO2019109802A1 (zh) * | 2017-12-05 | 2019-06-13 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的硼酸酯化合物的制备方法及其晶型 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
US10118937B1 (en) | 2018-01-03 | 2018-11-06 | Scinopharm Taiwan, Ltd. | Process for preparing ixazomib citrate and intermediates therefor |
CN110041353A (zh) * | 2018-01-16 | 2019-07-23 | 成都译山生物科技有限公司 | 一种新的硼酸水杨酸酯类衍生物及其药物组合物 |
US12054500B2 (en) | 2018-03-05 | 2024-08-06 | Arcus Biosciences, Inc. | Arginase inhibitors |
US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
CN110540547A (zh) * | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
CN112469480A (zh) | 2018-07-26 | 2021-03-09 | 默克专利股份公司 | 硼酸衍生物 |
JP7434273B2 (ja) * | 2018-08-02 | 2024-02-20 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | アゼチジン誘導体のボレート |
CN115403603A (zh) * | 2018-09-14 | 2022-11-29 | 成都奥璟生物科技有限公司 | 一种硼酸酯类药物及其用途 |
CN110357787A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 依沙佐米合成工艺研究 |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
WO2024006337A1 (en) | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Cyclic boronic esters and their uses |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
CN117964650B (zh) * | 2024-03-28 | 2024-06-07 | 成都硕德药业有限公司 | 一种枸橼酸伊沙佐米的制备方法 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US449082A (en) * | 1891-03-24 | milbeadt | ||
US2160413A (en) | 1935-04-16 | 1939-05-30 | Schering Ag | Polyiodo derivatives of acylamino acids and their salts and a method of making the same |
NZ203706A (en) | 1982-04-22 | 1986-03-14 | Squibb & Sons Inc | Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
JPS6233170A (ja) | 1985-08-07 | 1987-02-13 | Tokuyama Soda Co Ltd | 環状ポリエ−テル化合物 |
JPH0813759B2 (ja) | 1986-09-01 | 1996-02-14 | 富士写真フイルム株式会社 | アルコキシベンゼン誘導体の製造方法 |
JP2512303B2 (ja) | 1987-03-20 | 1996-07-03 | 呉羽化学工業株式会社 | 2−オキサゾリン−4,5−ジオンのフエニルヒドラゾン誘導体 |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) * | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5242904A (en) * | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US5159060A (en) * | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
MX9206628A (es) | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
EP0583536B1 (en) | 1992-08-14 | 1997-03-05 | The Procter & Gamble Company | Liquid detergents containing an alpha-amino boronic acid |
US5442100A (en) | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
US5492900A (en) * | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
US5935944A (en) * | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
US6060462A (en) * | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
FR2712602B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5614649A (en) * | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
JP3403009B2 (ja) | 1996-07-12 | 2003-05-06 | キヤノン株式会社 | 可動部材の変位と気泡成長を伴う液体吐出方法、該吐出方法に用いられる液体吐出ヘッド、ヘッドカートリッジ及びこれらを用いた液体吐出装置 |
US5834487A (en) | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
AU741802B2 (en) | 1997-02-15 | 2001-12-13 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts through inhibition of NF-kappaB |
CA2304622A1 (en) | 1997-09-25 | 1999-04-01 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases |
CA2314259A1 (en) | 1997-12-16 | 1999-06-24 | Robert Siman | Multicatalytic protease inhibitors for use as anti-tumor agents |
US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
AU6229699A (en) | 1998-10-26 | 2000-05-15 | Sumitomo Pharmaceuticals Company, Limited | Beta-amyloid formation inhibitors |
US6169076B1 (en) * | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
US6121149A (en) | 1999-04-22 | 2000-09-19 | Advanced Micro Devices, Inc. | Optimized trench/via profile for damascene filling |
KR100307027B1 (ko) | 1999-06-17 | 2001-11-01 | 서평원 | 액정 표시장치 및 이것을 이용한 이동 통신 단말기의 표시장치 |
AU5920400A (en) | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Cell-based assay systems for examining hcv ns3 protease activity |
SE0100714D0 (sv) | 2000-07-13 | 2001-02-28 | Ap Biotech Ab | Reaction vessel and method for distributing fluid in such a vessel |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
JP2002145848A (ja) * | 2000-11-10 | 2002-05-22 | Kyorin Pharmaceut Co Ltd | アルケニルアミノ酸誘導体及びその製造法 |
EP1217000A1 (en) * | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
EP3078667B1 (en) | 2001-01-25 | 2018-11-21 | The United States of America, represented by the Secretary, Department of Health and Human Services | Formulation of boronic acid compounds |
CN100415770C (zh) | 2001-05-30 | 2008-09-03 | 诺瓦提斯公司 | 2-{[n-(2-氨基-3-(杂芳基或芳基)丙酰基)-氨基酰基]-氨基}-烷基硼酸衍生物 |
DE10131283A1 (de) | 2001-06-28 | 2003-01-09 | Philips Corp Intellectual Pty | Phased Array Antenne |
WO2003033506A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant |
WO2003033507A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant |
JP4412586B2 (ja) | 2002-01-08 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 |
WO2003105860A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
US20060084592A1 (en) | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
JP2006509034A (ja) | 2002-09-09 | 2006-03-16 | トライジェン・リミテッド | 選択性トロンビン阻害のための非経口製剤に有用なボロン酸塩 |
TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
TWI345465B (en) * | 2003-08-14 | 2011-07-21 | Cephalon Inc | Proteasome inhibitors and methods of using the same |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
ME01975B (me) | 2004-03-30 | 2015-05-20 | Millennium Pharm Inc | Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline |
WO2005111008A2 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Compounds for enzyme inhibition |
WO2006008660A2 (en) | 2004-07-20 | 2006-01-26 | Affinium Pharmaceuticals, Inc. | Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) |
TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
CN101120006A (zh) * | 2005-02-11 | 2008-02-06 | 赛福伦公司 | 蛋白酶体抑制剂及其使用方法 |
KR20080007642A (ko) | 2005-04-29 | 2008-01-22 | 코산 바이오사이언시즈, 인코포레이티드 | 프로테아좀 억제제와 함께 17-aag 또는 17-ag 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법 |
KR20080030079A (ko) | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
JP2009519908A (ja) * | 2005-12-08 | 2009-05-21 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害活性を有する二環式化合物 |
EP2029153A2 (en) | 2006-01-27 | 2009-03-04 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
RU2409570C2 (ru) | 2006-02-03 | 2011-01-20 | Тайсо Фармасьютикал Ко., Лтд. | Производные триазола |
CL2007002499A1 (es) * | 2006-08-30 | 2008-03-14 | Phenomix Corp | Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. |
WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
UA97536C2 (en) * | 2007-08-06 | 2012-02-27 | Милленниум Фармасьютикалз, Инк. | Proteasome inhibitors |
US7442830B1 (en) * | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
ITMI20072397A1 (it) | 2007-12-20 | 2009-06-21 | Gambro Lundia Ab | Apparecchiatura medicale per il trattamento extracorporeo |
ES2585114T3 (es) * | 2008-06-17 | 2016-10-03 | Millennium Pharmaceuticals, Inc. | Compuestos de ésteres boronato y composiciones farmacéuticas de los mismos |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
BR112013026094A2 (pt) | 2011-04-29 | 2016-12-27 | Ericsson Telefon Ab L M | controle descentralizado de redução de interferência em um sistema de comunicação sem fio |
JP5724951B2 (ja) | 2012-06-11 | 2015-05-27 | 日立金属株式会社 | ネットワーク管理装置 |
JP6357023B2 (ja) | 2014-06-06 | 2018-07-11 | 任天堂株式会社 | 情報処理プログラム、情報処理装置、情報処理装置の制御方法および情報処理システム |
-
2009
- 2009-06-16 ES ES13191414.5T patent/ES2585114T3/es active Active
- 2009-06-16 PL PL09767050T patent/PL2318419T3/pl unknown
- 2009-06-16 MY MYPI2014003632A patent/MY171021A/en unknown
- 2009-06-16 ES ES09767050.9T patent/ES2541467T3/es active Active
- 2009-06-16 CN CN201710264997.5A patent/CN107266480A/zh active Pending
- 2009-06-16 EP EP13191409.5A patent/EP2730579A1/en not_active Withdrawn
- 2009-06-16 EP EP09767050.9A patent/EP2318419B1/en active Active
- 2009-06-16 EA EA201500431A patent/EA201500431A1/ru unknown
- 2009-06-16 DK DK13191414.5T patent/DK2730581T3/en active
- 2009-06-16 CN CN2013103488135A patent/CN103435638A/zh active Pending
- 2009-06-16 CN CN201310349472.3A patent/CN103497232A/zh active Pending
- 2009-06-16 CA CA2921946A patent/CA2921946C/en active Active
- 2009-06-16 GE GEAP200912730A patent/GEP201706703B/en unknown
- 2009-06-16 MX MX2013010325A patent/MX349769B/es unknown
- 2009-06-16 CN CN2013103491814A patent/CN103467565A/zh active Pending
- 2009-06-16 BR BRPI0915300A patent/BRPI0915300C1/pt active IP Right Grant
- 2009-06-16 EA EA201500430A patent/EA030685B1/ru not_active IP Right Cessation
- 2009-06-16 CN CN201710333805.1A patent/CN107253975A/zh active Pending
- 2009-06-16 US US12/485,344 patent/US20090325903A1/en not_active Abandoned
- 2009-06-16 DK DK09767050.9T patent/DK2318419T3/en active
- 2009-06-16 EP EP20130191412 patent/EP2730580A1/en not_active Withdrawn
- 2009-06-16 EA EA201170036A patent/EA027346B1/ru not_active IP Right Cessation
- 2009-06-16 EP EP19150417.4A patent/EP3536693A1/en active Pending
- 2009-06-16 CN CN201310349247XA patent/CN103450241A/zh active Pending
- 2009-06-16 CN CN201710292950.XA patent/CN107253966A/zh active Pending
- 2009-06-16 BR BR122014008750A patent/BR122014008750A2/pt not_active Application Discontinuation
- 2009-06-16 CA CA2727862A patent/CA2727862C/en active Active
- 2009-06-16 SG SG2013069851A patent/SG194349A1/en unknown
- 2009-06-16 MY MYPI2010005940A patent/MY155592A/en unknown
- 2009-06-16 NZ NZ624122A patent/NZ624122A/en unknown
- 2009-06-16 KR KR1020147019854A patent/KR101690571B1/ko active IP Right Grant
- 2009-06-16 KR KR1020147019860A patent/KR101741142B1/ko active IP Right Grant
- 2009-06-16 CN CN2009801230135A patent/CN102066386A/zh active Pending
- 2009-06-16 EA EA201500432A patent/EA201500432A1/ru unknown
- 2009-06-16 NZ NZ603236A patent/NZ603236A/en unknown
- 2009-06-16 NZ NZ624123A patent/NZ624123A/en unknown
- 2009-06-16 MX MX2013010326A patent/MX340186B/es unknown
- 2009-06-16 CN CN201310349618.4A patent/CN103497210A/zh active Pending
- 2009-06-16 GE GEAP2009012060 patent/GEP20135847B/en unknown
- 2009-06-16 SG SG10201701524XA patent/SG10201701524XA/en unknown
- 2009-06-16 JP JP2011514598A patent/JP5566380B2/ja active Active
- 2009-06-16 CN CN201710312608.1A patent/CN107266482A/zh active Pending
- 2009-06-16 EP EP13191413.7A patent/EP2733147A1/en not_active Withdrawn
- 2009-06-16 BR BR122014008753A patent/BR122014008753A2/pt not_active Application Discontinuation
- 2009-06-16 AU AU2009260778A patent/AU2009260778B2/en active Active
- 2009-06-16 BR BR122014008754A patent/BR122014008754A2/pt not_active Application Discontinuation
- 2009-06-16 KR KR1020147019858A patent/KR101704694B1/ko active IP Right Grant
- 2009-06-16 NZ NZ624121A patent/NZ624121A/en not_active IP Right Cessation
- 2009-06-16 SI SI200931201T patent/SI2318419T1/sl unknown
- 2009-06-16 PT PT97670509T patent/PT2318419E/pt unknown
- 2009-06-16 RS RS20150366A patent/RS54020B1/en unknown
- 2009-06-16 WO PCT/US2009/003602 patent/WO2009154737A1/en active Application Filing
- 2009-06-16 MX MX2010013642A patent/MX2010013642A/es active IP Right Grant
- 2009-06-16 UA UAA201403777A patent/UA115131C2/uk unknown
- 2009-06-16 MX MX2017014406A patent/MX358222B/es unknown
- 2009-06-16 KR KR1020177013867A patent/KR101860743B1/ko active IP Right Grant
- 2009-06-16 PT PT131914145T patent/PT2730581T/pt unknown
- 2009-06-16 KR KR1020117001181A patent/KR101691093B1/ko active IP Right Grant
- 2009-06-16 EP EP13191414.5A patent/EP2730581B1/en not_active Revoked
- 2009-06-17 PE PE2014000151A patent/PE20141078A1/es not_active Application Discontinuation
- 2009-06-17 TW TW103118482A patent/TWI542351B/zh not_active IP Right Cessation
- 2009-06-17 PE PE2014000153A patent/PE20141065A1/es not_active Application Discontinuation
- 2009-06-17 TW TW098120303A patent/TWI498333B/zh active
- 2009-06-17 PE PE2014000150A patent/PE20141064A1/es not_active Application Discontinuation
- 2009-06-17 TW TW103118480A patent/TWI543985B/zh active
- 2009-06-17 PE PE2014000152A patent/PE20141076A1/es not_active Application Discontinuation
- 2009-06-17 AR ARP090102187A patent/AR072162A1/es active IP Right Grant
- 2009-06-17 PE PE2009000877A patent/PE20100256A1/es active IP Right Grant
-
2010
- 2010-12-10 DO DO2010000384A patent/DOP2010000384A/es unknown
- 2010-12-16 CR CR11850A patent/CR11850A/es unknown
- 2010-12-16 IL IL210056A patent/IL210056B/en active IP Right Grant
- 2010-12-17 CL CL2010001475A patent/CL2010001475A1/es unknown
- 2010-12-21 ZA ZA2010/09177A patent/ZA201009177B/en unknown
- 2010-12-23 CO CO10161489A patent/CO6321289A2/es active IP Right Grant
-
2011
- 2011-01-13 MA MA33514A patent/MA32471B1/fr unknown
- 2011-01-17 EC EC2011010763A patent/ECSP11010763A/es unknown
- 2011-11-07 HK HK14111508.6A patent/HK1198252A1/xx unknown
- 2011-11-07 HK HK14111509.5A patent/HK1198253A1/xx unknown
- 2011-11-07 HK HK14111716.4A patent/HK1198254A1/xx unknown
- 2011-11-07 HK HK11111993.1A patent/HK1157786A1/xx unknown
- 2011-11-07 HK HK14111510.2A patent/HK1199260A1/zh not_active IP Right Cessation
- 2011-12-20 ZA ZA2011/09368A patent/ZA201109368B/en unknown
-
2012
- 2012-11-02 US US13/667,164 patent/US8859504B2/en active Active
-
2013
- 2013-06-25 ZA ZA2013/04728A patent/ZA201304728B/en unknown
-
2014
- 2014-05-14 EC ECSP14010763 patent/ECSP14010763A/es unknown
- 2014-05-19 JP JP2014103398A patent/JP2014169317A/ja not_active Withdrawn
- 2014-05-19 JP JP2014103397A patent/JP5926319B2/ja active Active
- 2014-05-19 JP JP2014103396A patent/JP6110813B2/ja active Active
- 2014-05-19 JP JP2014103395A patent/JP6010066B2/ja active Active
- 2014-08-01 US US14/449,275 patent/US9175017B2/en active Active
- 2014-08-01 US US14/449,328 patent/US9175018B2/en active Active
- 2014-08-25 IL IL234286A patent/IL234286A/en active IP Right Grant
- 2014-08-25 IL IL234285A patent/IL234285B/en active IP Right Grant
-
2015
- 2015-05-27 PH PH12015501193A patent/PH12015501193A1/en unknown
- 2015-05-27 PH PH12015501191A patent/PH12015501191B1/en unknown
- 2015-05-27 PH PH12015501192A patent/PH12015501192A1/en unknown
- 2015-06-02 HR HRP20150592TT patent/HRP20150592T1/hr unknown
- 2015-06-08 ZA ZA2015/04133A patent/ZA201504133B/en unknown
- 2015-06-16 CY CY20151100519T patent/CY1116435T1/el unknown
- 2015-10-12 US US14/880,776 patent/US20160031913A1/en not_active Abandoned
-
2016
- 2016-01-08 CR CR20160014A patent/CR20160014A/es unknown
- 2016-01-08 CR CR20160015A patent/CR20160015A/es unknown
-
2017
- 2017-05-04 NO NO2017016C patent/NO2017016I1/no unknown
- 2017-06-30 JP JP2017128843A patent/JP2017214396A/ja not_active Withdrawn
- 2017-09-12 US US15/701,791 patent/US20180002350A1/en not_active Abandoned
-
2018
- 2018-03-22 US US15/928,139 patent/US20180208609A1/en not_active Abandoned
- 2018-03-27 HK HK18104203.5A patent/HK1244810A1/zh unknown
- 2018-03-27 HK HK18104202.6A patent/HK1244827A1/zh unknown
- 2018-03-27 HK HK18104204.4A patent/HK1244811A1/zh unknown
- 2018-03-27 HK HK18104201.7A patent/HK1244809A1/zh unknown
- 2018-10-18 US US16/163,694 patent/US20190048028A1/en not_active Abandoned
-
2019
- 2019-01-29 US US16/260,596 patent/US10526351B2/en active Active
- 2019-05-08 US US16/406,159 patent/US20190263839A1/en not_active Abandoned
- 2019-09-13 US US16/570,065 patent/US10604538B2/en active Active
- 2019-11-29 JP JP2019216272A patent/JP2020055829A/ja not_active Withdrawn
-
2020
- 2020-02-12 US US16/788,824 patent/US20200181176A1/en not_active Abandoned
- 2020-04-24 US US16/857,227 patent/US11485746B2/en active Active
- 2020-09-01 US US17/009,199 patent/US20200392164A1/en not_active Abandoned
-
2021
- 2021-03-11 US US17/198,442 patent/US20210198289A1/en not_active Abandoned
- 2021-07-01 JP JP2021109909A patent/JP2021165288A/ja not_active Withdrawn
- 2021-09-23 US US17/483,724 patent/US20220009948A1/en not_active Abandoned
-
2023
- 2023-05-03 US US18/311,290 patent/US20230265111A1/en not_active Abandoned
- 2023-09-07 JP JP2023145377A patent/JP2023158150A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116435T1 (el) | Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων | |
CY1123470T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατοπαθειων | |
PH12014500053A1 (en) | Proteasome inhibitors | |
CY1118454T1 (el) | Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες | |
EA201170508A1 (ru) | Производные 1-амино-2-циклобутилэтилбороновой кислоты | |
EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
CY1116578T1 (el) | Αναστολεις της bromodomain και χρησεις αυτων | |
EA201170832A1 (ru) | Пуриновые соединения | |
CY1116216T1 (el) | Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου | |
EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
MY180594A (en) | Proteasome inhibitors | |
EA201791835A3 (ru) | Ингибиторы протеасом | |
CY1120307T1 (el) | Καινοφανεις ενωσεις επιλεκτικων ανταγωνιστων του υποδοχεα νκ-3, φαρμακευτικες συνθεσεις και μεθοδοι χρησης σε διαμεσολαβουμενες απο υποδοχεις νκ-3 διαταραχες | |
UA106205C2 (ru) | Соединения боронатного эфира, фармацевтическая композиция (варианты), которая содержит их, и способ их получения (варианты) | |
CY1116334T1 (el) | Νεο πολυμορφο |